SCYX - SCYNEXIS and Hansoh Pharmaceutical ink license deal for Ibrexafungerp development

SCYNEXIS ([[SCYX]] +0.2%) and Hansoh Pharmaceutical Group announces a strategic partnership and license agreement for the development and commercialization of Ibrexafungerp for the Greater China region.Ibrexafungerp is an oral antifungal product candidate under regulatory review for the treatment of vaginal yeast infection also known as vulvovaginal candidiasis.Under the terms of the agreement, Hansoh shall be responsible for the development, regulatory approval, and commercialization of ibrexafungerp in Greater China.SCYNEXIS will receive a $10M upfront payment and will also be eligible to receive development and commercial milestones, plus low double-digit royalties on net product sales.

For further details see:

SCYNEXIS and Hansoh Pharmaceutical ink license deal for Ibrexafungerp development